BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30505235)

  • 1. The mTOR pathway in treatment of epilepsy: a clinical update.
    Griffith JL; Wong M
    Future Neurol; 2018 May; 13(2):49-58. PubMed ID: 30505235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR dysregulation and tuberous sclerosis-related epilepsy.
    Curatolo P; Moavero R; van Scheppingen J; Aronica E
    Expert Rev Neurother; 2018 Mar; 18(3):185-201. PubMed ID: 29338461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis.
    Citraro R; Leo A; Constanti A; Russo E; De Sarro G
    Pharmacol Res; 2016 May; 107():333-343. PubMed ID: 27049136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epilepsy in the mTORopathies: opportunities for precision medicine.
    Moloney PB; Cavalleri GL; Delanty N
    Brain Commun; 2021; 3(4):fcab222. PubMed ID: 34632383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR inhibitors as a new therapeutic option for epilepsy.
    Curatolo P; Moavero R
    Expert Rev Neurother; 2013 Jun; 13(6):627-38. PubMed ID: 23739000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development.
    Jeong A; Wong M
    J Child Neurol; 2018 Jan; 33(1):55-63. PubMed ID: 29246093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into a spectrum of developmental malformations related to mTOR dysregulations: challenges and perspectives.
    Mühlebner A; Bongaarts A; Sarnat HB; Scholl T; Aronica E
    J Anat; 2019 Sep; 235(3):521-542. PubMed ID: 30901081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR as a potential treatment target for epilepsy.
    Wong M
    Future Neurol; 2012 Sep; 7(5):537-545. PubMed ID: 23620711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway.
    Zeng LH; Rensing NR; Wong M
    Mol Cell Pharmacol; 2009 Jan; 1(3):124-129. PubMed ID: 20419051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives.
    Overwater IE; Rietman AB; van Eeghen AM; de Wit MCY
    Ther Clin Risk Manag; 2019; 15():951-955. PubMed ID: 31440057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy.
    Goldstein HE; Hauptman JS
    Front Neurol; 2021; 12():639319. PubMed ID: 33643212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the mTOR signaling pathway in epilepsy.
    Meng XF; Yu JT; Song JH; Chi S; Tan L
    J Neurol Sci; 2013 Sep; 332(1-2):4-15. PubMed ID: 23773767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR inhibition in epilepsy: rationale and clinical perspectives.
    Ostendorf AP; Wong M
    CNS Drugs; 2015 Feb; 29(2):91-9. PubMed ID: 25633849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of mTOR inhibitors in epilepsy treatment.
    Sadowski K; Kotulska-Jóźwiak K; Jóźwiak S
    Pharmacol Rep; 2015 Jun; 67(3):636-46. PubMed ID: 25933981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.
    McDaniel SS; Wong M
    Neurosci Lett; 2011 Jun; 497(3):231-9. PubMed ID: 21354266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
    Schubert-Bast S; Rosenow F; Klein KM; Reif PS; Kieslich M; Strzelczyk A
    Epilepsy Behav; 2019 Feb; 91():94-98. PubMed ID: 29941212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures.
    Lechuga L; Franz DN
    Expert Rev Neurother; 2019 Oct; 19(10):913-925. PubMed ID: 31335226
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy.
    Wheless JW
    Epilepsy Behav Case Rep; 2015; 4():63-6. PubMed ID: 26543807
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.